Previous Article
Journal of Bacteriology, December 2007, p. 8765-8768, Vol. 189, No. 23
0021-9193/07/$08.00+0 doi:10.1128/JB.01215-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Amino Acid Toxicities of Escherichia coli That Are Prevented by Leucyl-tRNA Synthetase Amino Acid Editing
Vrajesh A. Karkhanis,
Anjali P. Mascarenhas, and
Susan A. Martinis*
Department of Biochemistry, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., 419 Roger Adams Laboratory, Box B-4, Urbana, Illinois 61801-3732
Received 27 July 2007/
Accepted 7 September 2007

ABSTRACT
Leucyl-tRNA synthetase (LeuRS) has evolved an editing function
to clear misactivated amino acids. An
Escherichia coli-based
assay was established to identify amino acids that compromise
the fidelity of LeuRS and translation. Multiple nonstandard
as well as standard amino acids were toxic to the cell when
LeuRS editing was inactivated.

TEXT
In the first step of protein synthesis, an aminoacyl-tRNA synthetase
(aaRSs) is responsible for linking a single standard amino acid
to its correct set of tRNA isoacceptors (
11,
20). About half
of the family of 20 aaRSs are challenged to distinguish among
closely related amino acids and have evolved amino-acid-editing
mechanisms to clear their mistakes (
10). These editing mechanisms
maintain translational fidelity by impeding the production of
"statistical proteins," which is hazardous to cell viability.
The fidelity of most aaRSs that edit is threatened by a limited number of noncognate standard amino acids. For example, isoleucyl-tRNA synthetase (IleRS) must distinguish between isoleucine and valine, which differ by a single missing methyl group (2, 5, 6, 9, 22, 23). Valyl-tRNA synthetase (ValRS) editing targets threonine, which has a hydroxyl group that is isosteric to the methyl moiety in valine (7, 8). Previously, we determined that leucyl-tRNA synthetase (LeuRS), which is homologous to IleRS and ValRS, misactivates a wide array of amino acids in vitro (19). Thus, we hypothesized that numerous structurally diverse amino acids might compete effectively for binding in the larger leucine-binding pocket of LeuRS (17) for aminoacylation to tRNALeu.
We sought to determine which of the amino acids that were misactivated by LeuRS might be detrimental to the cell if the editing activity of LeuRS was dysfunctional. This would also provide insight into which amino acids were actually targeted by the LeuRS editing activity in vivo to maintain the fidelity of translation. We employed the editing-defective TT/VV LeuRS mutant strain of Escherichia coli (26) to investigate the intracellular toxicity of LeuRS-misactivated amino acids. This mutated LeuRS has two conserved threonines that have been replaced by valines in the editing-active site (26). Aminoacylation is unaffected, but hydrolytic editing activity is abolished to stably produce mischarged Ile-tRNALeu in vitro.
We cotransformed the E. coli strain KL231, which has a temperature-sensitive LeuRS mutation (18) with plasmid pGP1-2, which carries the gene for T7 RNA polymerase (25), and plasmid pYZHAI3, which expresses the editing-defective TT/VV LeuRS mutant (26). Transformants were selected as described previously (12, 18). The editing-defective TT/VV LeuRS mutant enzyme as well as a wild-type LeuRS control (p15ec3-1 [19]) complemented the temperature-sensitive strain at 42°C (Fig. 1). In vitro aminoacylation assays indicated that mischarging by the TT/VV LeuRS mutant was slightly increased at 42°C compared to that at 30°C (data not shown), which could increase cell sensitivity to the editing defect at the higher temperature.
Previously, we showed that excess isoleucine was inhibitory
to the growth of
E. coli bacteria that were dependent on an
editing-defective LeuRS (
12). Herein, we expanded our toxicity
studies to include all of the standard amino acids to identify
those amino acids that threaten LeuRS fidelity in vivo. A zone
of growth inhibition, or a halo, around a central well that
contained concentrated nonleucine amino acids showed that among
the standard amino acids, isoleucine, valine, and methionine
were toxic to
E. coli cells that were dependent on the editing-defective
TT/VV LeuRS mutant for aminoacylation (Fig.
1A). We also tested
a series of nonstandard amino acids that accumulate in metabolic
pathways or act as signaling molecules within bacteria (
3,
13-
15,
24). Norvaline, norleucine, homoserine, and homocysteine yielded
significant halos (Fig.
1B). In contrast, cells that were complemented
by the wild-type LeuRS failed to produce a halo in the presence
of high concentrations (near the limits of saturation) of any
of these non-leucine amino acids. This demonstrates that the
robust posttransfer editing function of LeuRS protects the cell
from potential amino acid toxicities.
We also investigated the cell growth of E. coli KL231 cells harboring either the wild type or the editing-defective LeuRS TT/VV mutation in liquid minimal medium cultures. When the LeuRS TT/VV mutation was present, excess methionine or valine slowed growth rates in comparison to that of the cells complemented by the wild-type LeuRS (Fig. 2). In addition, these cells reached a lower plateau, indicating that growth was stunted, presumably as statistical protein mutations accumulated within the cell due to the LeuRS editing defect (Fig. 2). Likewise, liquid growth cultures showed that the nonstandard amino acids norleucine, norvaline, homocysteine, and homoserine reduced growth rates and lowered plateaus when E. coli was dependent on the editing-defective LeuRS (Fig. 2). These changes in growth patterns varied for different amino acids and between experiments due to the statistical nature of the accumulation of errors during protein synthesis.
We carried out a dose-dependent analysis of the amino acids
that were toxic to
E. coli KL231 in the presence of an editing-defective
LeuRS (Fig.
3). We also determined the 50% inhibitory concentration
(IC
50) values (± standard deviations) for the amino acids
to quantitate their toxicities, as follows: 27.0 ± 4.7
mM for isoleucine, 36.6 ± 4.2 mM for methionine, 46.3
± 25 mM for valine, and 14.1 ± 5.1 mM for homoserine.
The unbranched, aliphatic norvaline and norleucine exhibited
the most potent toxicities, with IC
50 values of 4.2 ±
2.8 mM and 8.2 ± 0.5 mM, respectively. By comparison,
the standard amino acid isoleucine had an IC
50 value of 27.0
± 4.7 mM. Despite repeated attempts, a reproducible IC
50 value for homocysteine could not be measured because of heterogeneity
in the sample and low solubility. Likewise, the IC
50 value for
valine varied significantly in repeated experiments because
its IC
50 value was high and approached the limits of solubility
under the conditions used. In addition, potential IC
50 values
for effects on the wild-type enzyme could not be measured because
of the relatively low solubility of each of these aliphatic
amino acids.
Overall, these combined results suggest that nonstandard amino
acids might be a greater threat to the LeuRS-dependent fidelity
of protein synthesis than standard amino acids. In the case
of norvaline, it has been shown that intracellular levels of
norvaline are low compared to those of leucine but can be significantly
increased under conditions that induce high expression of recombinant
proteins in
E. coli (
1). Interestingly, norvaline has been shown
to at least partially bypass the LeuRS editing mechanism and
to substitute for leucine under cell growth conditions that
require high expression of recombinant proteins in
E. coli (
1).
However, our results emphasize that norvaline is subject to
LeuRS amino acid editing at levels that control its toxicity.
Our investigation supports the possibility that LeuRS has the complicated challenge of discriminating between multiple standard and nonstandard amino acids in vivo. As with other aaRSs (4, 21), LeuRS is required to block amino acid toxicity to the cell with high translational fidelity. While some aaRSs can achieve this level of discrimination within a single aminoacylation-active site to maintain accurate protein synthesis, LeuRS and other aaRSs have acquired a second active hydrolytic site to edit misactivated amino acids (10). Inactivation of the LeuRS editing activity clearly hinders cell growth. This is likely due to a steady accumulation of errors during translation that would yield misfolded and/or inactivated proteins (16). As these statistically generated protein mutations accumulate, intracellular processes would be compromised to lower cell viability and survival. These high fidelity requirements of LeuRS for protein synthesis are consistent with the early acquisition of its editing domain during evolution (27).

ACKNOWLEDGMENTS
This work was supported by the National Institutes of Health
(GM63789).
We thank A. M. Williams for technical assistance and advice.

FOOTNOTES
* Corresponding author. Mailing address: Department of Biochemistry, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., 419 Roger Adams Laboratory, Box B-4, Urbana, Illinois 61801-3732. Phone: (217) 244-2405. Fax: (217) 244-5858. E-mail:
martinis{at}life.uiuc.edu 
Published ahead of print on 21 September 2007. 
Present address: Program in Gene Function and Expression, University of Massachusetts Medical School, Aaron Lazare Medical Research Building-670C, 364 Plantation Street, Worcester, MA 01605-4321. 

REFERENCES
1 - Apostol, I., J. Levine, J. Lippincott, J. Leach, E. Hess, C. B. Glascock, M. J. Weickert, and R. Blackmore. 1997. Incorporation of norvaline at leucine positions in recombinant human hemoglobin expressed in Escherichia coli. J. Biol. Chem. 272:28980-28988.[Abstract/Free Full Text]
2 - Baldwin, A. N., and P. Berg. 1966. Transfer ribonucleic acid-induced hydrolysis of valyladenylate bound to isoleucyl ribonucleic acid synthetase. J. Biol. Chem. 241:839-845.[Abstract/Free Full Text]
3 - Bogosian, G., B. N. Violand, E. J. Dorward-King, W. E. Workman, P. E. Jung, and J. F. Kane. 1989. Biosynthesis and incorporation into protein of norleucine by Escherichia coli. J. Biol. Chem. 264:531-539.[Abstract/Free Full Text]
4 - Döring, V., H. D. Mootz, L. A. Nangle, T. L. Hendrickson, V. de Crécy-Lagard, P. Schimmel, and P. Marliere. 2001. Enlarging the amino acid set of Escherichia coli by infiltration of the valine coding pathway. Science 292:501-504.[Abstract/Free Full Text]
5 - Eldred, E. W., and P. R. Schimmel. 1972. Rapid deacylation by isoleucyl transfer ribonucleic acid synthetase of isoleucine-specific transfer ribonucleic acid aminoacylated with valine. J. Biol. Chem. 247:2961-2964.[Abstract/Free Full Text]
6 - Fersht, A. R. 1977. Editing mechanisms in protein synthesis. Rejection of valine by the isoleucyl-tRNA synthetase. Biochemistry 16:1025-1030.[CrossRef][Medline]
7 - Fersht, A. R., and C. Dingwall. 1979. Establishing the misacylation/deacylation of the tRNA pathway for the editing mechanism of prokaryotic and eukaryotic valyl-tRNA synthetases. Biochemistry 18:1238-1245.[CrossRef][Medline]
8 - Fukai, S., O. Nureki, S. Sekine, A. Shimada, J. Tao, D. G. Vassylyev, and S. Yokoyama. 2000. Structural basis for double-sieve discrimination of L-valine from L-isoleucine and L-threonine by the complex of tRNA(Val) and valyl-tRNA synthetase. Cell 103:793-803.[CrossRef][Medline]
9 - Fukunaga, R., and S. Yokoyama. 2006. Structural basis for substrate recognition by the editing domain of isoleucyl-tRNA synthetase. J. Mol. Biol. 359:901-912.[CrossRef][Medline]
10 - Hendrickson, T. L., V. de Crécy-Lagard, and P. Schimmel. 2004. Incorporation of nonnatural amino acids into proteins. Annu. Rev. Biochem. 73:147-176.[CrossRef][Medline]
11 - Ibba, M., and D. Söll. 2000. Aminoacyl-tRNA synthesis. Annu. Rev. Biochem. 69:617-650.[CrossRef][Medline]
12 - Karkhanis, V. A., M. T. Boniecki, K. Poruri, and S. A. Martinis. 2006. A viable amino acid editing activity in the leucyl-tRNA synthetase CP1-splicing domain is not required in the yeast mitochondria. J. Biol. Chem. 281:33217-33225.[Abstract/Free Full Text]
13 - Kisumi, M., M. Sugiura, and I. Chibata. 1976. Biosynthesis of norvaline, norleucine, and homoisoleucine in Serratia marcescens. J. Biochem. (Tokyo) 80:333-339.[Abstract/Free Full Text]
14 - Kisumi, M., M. Sugiura, J. Kato, and I. Chibata. 1976. L-Norvaline and L-homoisoleucine formation by Serratia marcescens. J. Biochem. (Tokyo) 79:1021-1028.[Abstract/Free Full Text]
15 - Lazzerini, P. E., P. L. Capecchi, E. Selvi, S. Lorenzini, S. Bisogno, M. Galeazzi, and F. Laghi Pasini. 2007. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun. Rev. 6:503-509.[CrossRef][Medline]
16 - Lee, J. W., K. Beebe, L. A. Nangle, J. Jang, C. M. Longo-Guess, S. A. Cook, M. T. Davisson, J. P. Sundberg, P. Schimmel, and S. L. Ackerman. 2006. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature 443:50-55.[CrossRef][Medline]
17 - Lincecum, T. L., Jr., and S. A. Martinis. 2000. The tRNA synthetase proofreading and editing active sites: a novel antibiotic target. SAAS Bull. Biochem. Biotechnol. 13:25-33.
18 - Low, B., F. Gates, T. Goldstein, and D. Söll. 1971. Isolation and partial characterization of temperature-sensitive Escherichia coli mutants with altered leucyl- and seryl-transfer ribonucleic acid synthetases. J. Bacteriol. 108:742-750.[Abstract/Free Full Text]
19 - Martinis, S. A., and G. E. Fox. 1997. Non-standard amino acid recognition by Escherichia coli leucyl-tRNA synthetase. Nucleic Acids Symp. Ser. 36:125-128.[Medline]
20 - Martinis, S. A., and P. Schimmel. 1992. Aminoacyl-tRNA synthetases, p. 887-901. In F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), General features and relationships in Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed. ASM Press, Washington, DC.
21 - Nangle, L. A., V. De Crécy Lagard, V. Doring, and P. Schimmel. 2002. Genetic code ambiguity. Cell viability related to the severity of editing defects in mutant tRNA synthetases. J. Biol. Chem. 277:45729-45733.[Abstract/Free Full Text]
22 - Nureki, O., D. G. Vassylyev, M. Tateno, A. Shimada, T. Nakama, S. Fukai, M. Konno, T. L. Hendrickson, P. Schimmel, and S. Yokoyama. 1998. Enzyme structure with two catalytic sites for double-sieve selection of substrate. Science 280:578-582.[Abstract/Free Full Text]
23 - Schreier, A. A., and P. R. Schimmel. 1972. Transfer ribonucleic acid synthetase catalyzed deacylation of aminoacyl transfer ribonucleic acid in the absence of adenosine monophosphate and pyrophosphate. Biochemistry 11:1582-1589.[CrossRef][Medline]
24 - Steindler, L., and V. Venturi. 2007. Detection of quorum-sensing N-acyl homoserine lactone signal molecules by bacterial biosensors. FEMS Microbiol. Lett. 266:1-9.[CrossRef][Medline]
25 - Tabor, S., and C. C. Richardson. 1985. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc. Natl. Acad. Sci. USA 82:1074-1078.[Abstract/Free Full Text]
26 - Zhai, Y., and S. A. Martinis. 2005. Two conserved threonines collaborate in the Escherichia coli leucyl-tRNA synthetase amino acid editing mechanism. Biochemistry 44:15437-15443.[CrossRef][Medline]
27 - Zhao, M. W., R. Hao, J. F. Chen, F. Martin, G. Eriani, and E. D. Wang. 2003. Enzymes assembled from Aquifex aeolicus and Escherichia coli leucyl-tRNA synthetases. Biochemistry 42:7694-7700.[CrossRef][Medline]
Journal of Bacteriology, December 2007, p. 8765-8768, Vol. 189, No. 23
0021-9193/07/$08.00+0 doi:10.1128/JB.01215-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Sikora, M., Jakubowski, H.
(2009). Homocysteine editing and growth inhibition in Escherichia coli. Microbiology
155: 1858-1865
[Abstract]
[Full Text]
-
Boniecki, M. T., Vu, M. T., Betha, A. K., Martinis, S. A.
(2008). From the Cover: CP1-dependent partitioning of pretransfer and posttransfer editing in leucyl-tRNA synthetase. Proc. Natl. Acad. Sci. USA
105: 19223-19228
[Abstract]
[Full Text]
-
Yao, P., Zhou, X.-L., He, R., Xue, M.-Q., Zheng, Y.-G., Wang, Y.-F., Wang, E.-D.
(2008). Unique Residues Crucial for Optimal Editing in Yeast Cytoplasmic Leucyl-tRNA Synthetase Are Revealed by Using a Novel Knockout Yeast Strain. J. Biol. Chem.
283: 22591-22600
[Abstract]
[Full Text]